ValuEngine cut shares of Oncolytics Biotech (OTCMKTS:ONCYF) from a sell rating to a strong sell rating in a research note issued to investors on Friday morning.

Separately, Zacks Investment Research lowered Oncolytics Biotech from a hold rating to a sell rating in a research note on Friday, August 11th.

Oncolytics Biotech (OTCMKTS ONCYF) traded down $0.01 during trading hours on Friday, reaching $0.53. The company’s stock had a trading volume of 46,491 shares, compared to its average volume of 192,394. Oncolytics Biotech has a 1 year low of $0.14 and a 1 year high of $0.85.

TRADEMARK VIOLATION WARNING: This report was published by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was stolen and republished in violation of international copyright & trademark laws. The original version of this report can be viewed at

About Oncolytics Biotech

Oncolytics Biotech Inc is a development-stage company. The Company is focused on the development of REOLYSIN, its cancer therapeutic. The Company’s clinical program is made up of a registration program that includes muscle-invasive bladder cancer and glioma cancer, over six randomized Phase II clinical trials and approximately six other investigative clinical trials.

Receive News & Ratings for Oncolytics Biotech Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech Inc. and related companies with's FREE daily email newsletter.